00239.HK
Pak Fah Yeow International Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 2.50
−0.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 419.7M | 213.9M | 236.9M | 259.3M | 147.2M |
| Cost of Revenue | 105.7M | 80.7M | 33.7M | 91.7M | 73.1M |
| Gross Profit | 314.0M | 133.1M | 203.2M | 167.6M | 74.1M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 70.8M | 15.0M | 57.4M | 17.0M | 18.8M |
| General & Admin Expense | 24.6M | 4.9M | 45.5M | 6.2M | 5.6M |
| Selling & Marketing Expense | 11.9M | 10.2M | 11.9M | 10.8M | 13.2M |
| Other Expenses | 28.9M | 8.6M | 47.9M | 72.6M | 9.0M |
| Total Operating Expenses | 99.7M | 23.6M | 105.4M | 89.6M | 27.8M |
| Cost and Expenses | 205.4M | 104.4M | 139.1M | 116.1M | 101.0M |
| Operating Income (EBIT) | 214.3M | 109.5M | 98.3M | 143.0M | 46.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 1.1M | 546.0K | 584.0K | 615.0K | 644.0K |
| Net Interest Income | (1.1M) | (546.0K) | (584.0K) | (615.0K) | (644.0K) |
| Other Non-Op Income/Expense | (12.8M) | (2.0M) | (584.0K) | (14.2M) | (8.5M) |
| Non-Operating Income (excl Interest) | (12.6M) | — | 27.0M | 13.6M | 7.8M |
| EBT (Pre-Tax Income) | 201.5M | 107.5M | 97.8M | 128.8M | 37.8M |
| Income Tax Expense | 31.6M | 16.2M | 19.1M | 23.8M | 7.8M |
| Bottom Line | |||||
| Net Income | 169.9M | 91.3M | 78.6M | 105.0M | 30.0M |
| Earnings from Cont. Ops | 169.9M | 91.3M | 78.6M | 105.0M | 30.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 169.9M | 91.3M | 78.6M | 105.0M | 30.0M |
| Per Share | |||||
| Basic EPS | HK$0.55 | HK$0.29 | HK$0.25 | HK$0.34 | HK$0.10 |
| Diluted EPS | HK$0.55 | HK$0.29 | HK$0.25 | HK$0.34 | HK$0.10 |
| Revenue Per Share | HK$1.35 | HK$0.69 | HK$0.76 | HK$0.83 | HK$0.47 |
| Shares | |||||
| Basic Shares Outstanding | 311.6M | 311.6M | 311.6M | 311.6M | 311.6M |
| Diluted Shares Outstanding | 311.6M | 311.6M | 311.6M | 311.6M | 311.6M |
| Profitability Metrics | |||||
| EBITDA | 238.3M | 115.4M | 105.7M | 136.8M | 45.9M |
| D&A | 11.4M | 5.8M | 7.4M | 7.4M | 7.5M |
| EBIT | 226.9M | 109.5M | 98.3M | 129.4M | 38.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026